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Abstract The diadenosine oligophosphates (ApnA) were dis-
covered in the mid-sixties in the course of studies on aminoacyl-
tRNA synthetases (aaRS). Now, more than 30 years later, about
300 papers have been published around these substances in
attempt to decipher their role in cells. Recently, ApnA have
emerged as intracellular and extracellular signalling molecules
implicated in the maintenance and regulation of vital cellular
functions and become considered as second messengers. Great
variety of physiological and pathological effects in mammalian
cells was found to be associated with alterations of ApnA levels
(n from 2 to 6) and Ap3A/Ap4A ratio. Cell differentiation and
apoptosis have substantial and opposite effects on Ap3A/Ap4A
ratio in cultured cells. A human Ap3A hydrolase, Fhit, appeared
to be involved in protection of cells against tumourigenesis. Ap3A
is synthesised by mammalian u synthetase (TrpRS) which in
contrast to most other aaRS is unable to synthesise Ap4A and is
an interferon-inducible protein. Moreover, Ap3A appeared to be
a preferred substrate for 2-5A synthetase, also interferon-
inducible, priming the synthesis of 2P adenylated derivatives of
Ap3A, which in turn may serve as substrates of Fhit. Tumour
suppressor activity of Fhit is assumed to be associated with
involvement of the FhitWAp3A complex in cytokine signalling
pathway(s) controlling cell proliferation. The ApnA family is
potentially a novel class of signal-transducing molecules whose
functions are yet to be determined.
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1. Introduction
Diadenosine oligophosphates (ApnA) are made up of two
adenosine moieties joined in 5P-5P linkage by a chain from two
to six phosphodiester linkages. These compounds were discov-
ered by P. Zamecnik and his co-workers in the mid-sixties
(reviewed in [1]) but the ¢rst indication of the putative phys-
iological role of ApnA appeared only 10 years later when a
correlation between Ap4A concentration and proliferative sta-
tus of mammalian cells has been demonstrated [2]. In prokar-
yotes, heat shock and oxidative stress cause ApnA accumula-
tion [3,4], and for this reason these molecules were considered
as pleiotropically acting alarmones [5]. Further studies dem-
onstrated a ubiquitous occurrence of ApnA in the whole spec-
trum of organisms from bacteria to higher eukaryotes.
Although the role of ApnA in stress response remains un-
known for eukaryotes, in bacteria ApnA binds to and inhibit
the oxidative stress-related proteins [6,7]. The earlier phase of
ApnA investigations was summarised in several reviews [8^
14].
Till the late eighties the role of ApnA in higher eukaryotes
remained controversial. More recently, due to e¡orts of many
groups, ApnA have emerged as putative low-molecular extra-
and intracellular signals implicated in the most essential cel-
lular functions. The aim of this review is to summarise brie£y
the recent observations on the possible roles of ApnA mainly
in higher eukaryotes.
If ApnA do play important but unknown roles in cell me-
tabolism, one should observe at least two phenomena: phys-
iological e¡ects on various organisms, cell types, tissues, or
organs induced by ApnA in vivo and/or in vitro, and depend-
ence of ApnA concentrations in various cell types or organ-
isms on external and/or internal environmental factors and
physiological or pathological cell status. If both of these pre-
requisites are met, more sophisticated biochemical analysis
would be required to elucidate the role of these molecules in
the framework of cellular regulation.
2. ApnA are physiologically active and respond to various
factors
Examples of the e¡ects observed with ApnA are given in
Table 1. Some interesting features emerge from examination
of even this incomplete set of data. Many entirely di¡erent
tissues or cells respond to ApnA (heart, hyppocampus, sperm,
hepatocytes neutrophils, pancreatic cells, etc.) indicating the
involvement of ApnA family in wide-spread biochemical
events, not restricted to any specialised cell type or tissue.
The other important feature of ApnA e¡ects is a great variety
of responses that occurs in various cell types after adminis-
tration or addition of ApnA (Table 1, left column). Some
e¡ects are closely associated with nuclear functions (e.g. stim-
ulation of DNA synthesis, mitogenic activity, activation of
gene transcription), others involve membranes (e.g. induction
of Ca2 oscillations and release, inhibition of KATP channels,
etc.). Some e¡ects occur with cells and tissues as whole entities
(e.g. inhibition of sperm motility, decrease of coronary perfu-
sion pressure, vasoconstrictor and vasodilator actions, preven-
tion of aggregation of human platelets induced by ADP).
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A tight relation between the metabolic state of cardiac
muscle and the level of Ap5A was revealed [15]. Ischemia
induced a 10-fold decrease in cardiac Ap5A levels where the
major sensor of metabolic stress is the ATP-sensitive K
channel [16] an opening of which promotes cellular survival
under ischemic injury. It is suggested that the nucleotide bind-
ing domains of KATP channelWprotein complex may serve as
targets for Ap5A [15,17]. ApnA evoked inward and outward
ionic current £ows by activating purinoreceptors in Xenopus
laevis follicular oocytes [18]. Inward currents were mediated
by a suramin-sensitive P2 receptor which showed at 10 WM of
ApnA the following agonist potency order: Ap4AsATPs
Ap3A. Outward currents were mediated by a theophylline-
sensitive P1 receptor which possesses an agonist potency of
Ap2AsATPEAp4A. Control experiments showed that there
was no breakdown of the ApnA to ATP, ADP, or AMP. All
ApnA tested so far (n from 2 to 6) stimulated an increase in
intracellular concentration of Ca2 in human neutrophils.
This increase was abolished if cells were pretreated with
pertussis toxin known to interfere with activity of G proteins
[19].
Neutrophyl apoptosis could be delayed by inoculating the
cells with ATP, Ap3A, or Ap4A [20]. Moreover, addition of
these compounds together with a cytokine (granulocyte-mac-
rophage colony-stimulating factor) resulted in more pro-
nounced protection from apoptosis that was observed during
incubation with either Ap4A or the cytokine. ApnA-induced
e¡ects do not necessarily have the complex physiological na-
ture; for example, rat liver glycogen phosphorylase is acti-
vated by ApnA [21].
By no means, this list of ApnA e¡ects is incomplete and will
be extended tremendously in the coming years. But even the
limited number of examples clearly demonstrates a high var-
iability of cell and tissue targets accompanied by a wide di-
versity of the induced e¡ects. The most probable assumption
that uni¢es these highly diverse patterns is to consider ApnA
family as the signal transduction molecules. If this hypothesis
suggested by several groups adequately re£ects present-state
understanding of ApnA role, then one should expect to ¢nd
multiple factors that transmit their signals via changes in the
concentration of ApnA in response to their action. Table 2
shows that this prediction is supported by many observations.
Most remarkably, interferon causes entirely opposite e¡ects
on the Ap4A and Ap3A levels, 10-fold decrease and 3^5-
fold increase, respectively. Consequently, the Ap4A/Ap3A ra-
tio is changed 30^50-fold. Interferons are well known to cause
an inhibition of cell proliferation. On the other hand, in pro-
liferating cells Ap4A increases tremendously, opposite to the
resting cells. Heat shock induces in chicken erythrocytes a 10-
fold increase of Ap4A concentration. ApnA stimulate prolif-
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Table 1
Examples of physiological e¡ects associated with ApnA
E¡ect Target cells or tissues ApnA Reference
Inhibition of KATP channels, Ki 14^17 WM Myocardium Ap4A, Ap5A, Ap6A [22]
Inhibition of KATP channels, Ki 17 WM Pancreatic L cells (mice) Ap3A, Ap4A [23]
High probability of KATP channel opening at
ischemia
Guinea-pig myocardium Ap5A [15]
Activation of Egr-1 gene, mitogenic e¡ect,
stimulation of DNA synthesis
Cultured renal mesangial cells (rats) ApnA (n = 3^6) [24]
Induction of Ca2 oscillations Hepatocytes (rats) Ap3A, Ap4A [25]
Priming of the respiratory burst of oxidase activity Human neutrophils Ap3A, Ap4A, probably non-speci¢c
ATP is more active
[26]
Negative feedback for excitation Hippocampus Ap4A, Ap5A [27]
Inhibition of sperm motility Human spermatozoa Ap3A, Ap4A [28]
Decrease of coronary perfusion pressure Isolated rabbit hearts Ap3A, Ap4A [29]
Regulation of Ca2 release via ryanodine receptors Hepatocytes, skeletal muscle, cardiac
muscle
Ap3A, Ap4A [30]
Glycogen phosphorylase activation Rat liver cells Ap3A, Ap4A [21]
Vasoconstrictor and vasodilator actions Rat mesenteric arteries, isolated rat
perfused kidney
ApnA (n = 2^6) [31,32]
Antitrombolytic e¡ect, antagonists of ADP-induced
aggregation of human platelets
Human and rabbit platelets Ap4A and its non-hydrolysable
analog
[33]
Increase in intracellular Ca2 Human neutrophils ApnA (n = 3^6) [19]
Stimulation of gluconeogenesis Isolated rat proximal tubules Ap3A, Ap4A, ATP [34]
Inhibition of adenosine kinase activity Rat liver ApnA [35]
Control of timing of cell division E. coli Ap4A [36]
Delay of apoptosis Neutrophils Ap5A, Ap6A [20]
Table 2
Examples of alterations of ApnA concentrations induced by various factors
Inducer Tissue or cells ApnA E¡ect Reference
Interferon L Human cultured cells Ap4A 10-fold decrease [37]
Interferons K and Q Human cultured cells Ap3A 3^5-fold accumulation [38]
Glucose Murine pancreatic cells Ap3A, Ap4A 30^70-fold accumulation [23]
Heat shock Chicken erythrocytes Ap4A 10-fold increase [39]
Phorbol ester (TPA) Promyelocytic human cell line HL60 Ap3A 4^5-fold increase [40]
VP16 (topoisomerase II inhibitor, inducer
of apoptosis)
Promyelocytic human cell line HL60 Ap3A, Ap4A 3-fold decrease, 4-fold increase [40]
Ischemia Guinea-pig myocardium Ap5A 10-fold increase [15]
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eration of cultured mesangial cells and augment mesangial cell
growth induced by other mitogens released from platelets [24].
Ap3A accumulation was observed after induction of cell dif-
ferentiation by phorbol ester in promyelocytic cell line HL60.
In contrast, when HL60 cells were induced to undergo apop-
tosis by VP16, an inhibitor of DNA topoisomerase II, Ap3A
concentration dropped down while Ap4A concentration in-
creased (see references in Table 2).
Glucose at concentrations inducing insulin release from
pancreatic murine cells produces a 30- to 70-fold increase in
Ap3A and Ap4A concentrations in L cells [23]. These concen-
trations are su⁄cient to inhibit ATP-regulated K channels
when applied to the intracellular side of excised membrane
patches from these cells in culture. The authors arrive to the
conclusion that Ap3A and Ap4A act as second messengers
mediating a glucose-induced blockage of the ATP-dependent
potassium channel [23].
In many physiological manifestations Ap3A and Ap4A pos-
sess similar but not identical activities, in some cases resem-
bling those of ATP and ADP. However, in other systems, very
di¡erent and even opposite e¡ects were observed for ApnA
depending on oligophosphate chain length. For example,
ApnA with four or more phosphates are vasoconstrictors in
rat mesenteric arteries, while those with three or less phos-
phates are vasodilators [31].
Data summarised in Table 2 are consistent with the signal
transduction hypothesis since classical inducers of di¡erent
cell status cause well-de¢ned alterations of intracellular con-
centrations of various members of ApnA family.
3. ApnA binding proteins (APNAB)
The major pathway for signal-transducing molecules to per-
form their functions goes through binding to proteins. The
classical examples of such kind of interactions are provided
by binding of hormones to their receptors and by GTP/GDP
binding to the members of G protein family. If the signal
transduction hypothesis for ApnA family is correct, the struc-
tural dissimilarities between the various members of ApnA
family caused by the length of the oligophosphate chain
may result in the di¡erent patterns of binding proteins for
each ApnA molecule. If a single protein binds ApnA non-
selectively toward phosphate chain length, signal transduction
may be modulated by di¡erent protein conformational states
or by charge di¡erences induced by di¡erent ApnA molecules.
Finally, a single protein may bind several ApnA but with
di¡erent a⁄nity and in this case the concentrations of various
ApnA become essential.
In fact, APNAB do occur in various cell types (Table 3).
Roughly, APNAB can be categorised into four groups: (a)
receptors located at the cell surface and most probably in-
volved in signal transduction from an environment inside
the cell (the structure and function of these receptors have
been recently reviewed [60]); (b) enzymes utilising ApnA as
substrates; (c) other enzymes that bind ApnA but do not
metabolise them; (d) other proteins, probably most of them
yet unidenti¢ed.
Among APNAB are haemoglobin, glycogen phosphorylase,
glyceraldehyde-3-phosphate dehydrogenase, DNA polymerase
K associated protein. Hormones and hormone-like factors are
able to bind ApnA for example to acidic ¢broblast growth
factor and granulocyte-macrophage colony-stimulating factor.
These observations imply that ApnA when bound to speci¢c
ligands may modulate signal transduction induced by these
molecules. In some cases the speci¢city of the binding towards
di¡erent members of ApnA family and other adenosine deriv-
atives was relatively low, in other instances the spectrum of
compounds tested for binding speci¢city was rather narrow.
The major problem regarding APNAB is related to biological
signi¢cance of this binding and its functional consequences. It
might be of particular interest to isolate proteins with narrow
speci¢city towards ApnA derivatives, i.e. those that bind for
example Ap4A but not Ap3A and vice versa. If successful,
speci¢c ApnA binders may be very helpful in elucidating the
signal transduction pathway from ApnA to target molecules.
The Ap4A binding capacity [41] of uracil-DNA glycosylase/
glyceraldehyde-3-phosphate dehydrogenase (UDG/GAPDH)
is particularly interesting, because this enzyme also binds to
various RNAs including tRNAs and to mammalian TrpRS
[42]. It seems quite possible that Ap3A synthesised by TrpRS
(see Sections 4 and 5) could be also bound to UDG/GAPDH.
Since both UDG/GAPDH and TrpRS [43] are present in nu-
clei apart of being cytosolic enzymes, it is tempting to spec-
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Table 3
Examples of ApnA binding proteins (APNAB)
ApnA Binding protein Comments Reference
Ap3A, Ap4A P2 purine receptors Rat liver cells, guinea-pig vas deferens [18,44,45]
Ap4A Glyceraldehyde-3-phosphate dehydrogenase/uracil-DNA glycosylase HeLa cell nuclear extract 37 kDa [41]
Ap4A Acidic ¢broblast growth factor Probably non-speci¢c binding [46]
Ap4A, Ap5A, Ap6A Surface receptors of murine brain and heart cells 30 kDa [47^50]
Ap4A, not Ap3A DNA polymerase associated protein 200 kDa, subunit 22 kDa [51,52]
Ap4A Ap4A binding protein 90 kDa X. laevis [53]
Ap4A Brain membrane receptor Kd 0.71 WM [54]
Ap3A, Ap4A, ATP Granulocyte-macrophage colony-stimulating factor Binding causes delay in apoptosis [55]
Ap3A Diadenosine triphosphate hydrolase, Fhit Ap3A is a substrate for this enzyme [56]
Ap4A Receptor of ApnA Binding is inhibited by tripeptide Arg-
Gly-Ser
[57]
Ap4A Diadenosine tetraphosphate hydrolase Enzyme substrate tomato [58]
Ap4A Heat shock protein ClpB E. coli [59]
Fig. 1. Synthesis of Ap4A and Ap3A by aminoacyl-tRNA synthe-
tases (aaRS) in the absence of cognate tRNA.
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ulate that a ternary TrpRSWAp3AWUDG/GAPDH complex
may take part both in cytoplasmic and/or nuclear events,
for instance, in DNA repair.
4. ApnA metabolism
The best known reaction leading to the formation of Ap4A
is catalysed by aaRS (Fig. 1). It starts with the formation of
an enzyme-bound aminoacyl adenylate, which is the normal
intermediate in the synthesis of aminoacyl-tRNA. In the ab-
sence of tRNA the fate of the enzyme-bound aminoacyl ad-
enylate is determined by the competition of several reactions.
The reverse reaction results in the formation of ATP and
amino acid. Alternatively, aminoacyl adenylate can be at-
tacked by the pyrophosphate moiety of ATP leading to for-
mation of Ap4A, or hydrolysed, or dissociated from the en-
zyme. In the absence of substrate tRNA the reaction
equilibrium is shifted signi¢cantly towards pyrophosphoroly-
sis of the aminoacyl adenylate. Cleavage of PPi formed in the
course of amino acid activation by inorganic pyrophosphatase
changes the situation and activates substantially the Ap4A
synthesis.
Majority of aaRS catalyses the synthesis of Ap4A (reviewed
in [11,12,61]). Exceptions are ArgRS and GlnRS of any ori-
gin. Inability of ArgRS and GlnRS to produce Ap4A is re-
lated to the fact that both of these enzymes belong to the
group of aaRS capable of aminoacyl adenylate formation
only in the presence of cognate tRNA. However, as men-
tioned above, presence of tRNA in most cases inhibits
Ap4A synthesis. It seems very likely that the third member
of this group, GluRS also lacks the Ap4A-synthesising activ-
ity. Mammalian TrpRS produces only Ap3A due to some
peculiarities of its catalytic mechanism [61,62]. Ap4A synthesis
by some of aaRS is activated by Zn2 while the activity of the
majority of aaRS is not a¡ected by this ion (see [11,12] and
references therein).
Along with ATP, aaRS also utilise any nucleoside oligo-
phosphates (NDP, NTP, ppGpp, etc.) as substrates resulting
in formation of the family of adenylated dinucleoside oligo-
phosphates (reviewed in [11,12]). Non-nucleotidic molecules
like inorganic triphosphate or thiamine pyrophosphate may
also serve as donors of pyrophosphate groups in this reaction,
resulting in synthesis of corresponding adenylated compounds
(see [13]).
Structural framework for Ap4A formation by SerRS from
Thermus thermophilus was deduced from the crystallographic
data [63]. A second ATP molecule can bind to enzymeWadeny-
late complex with its Q-phosphate in the same position as the
L-phosphate of the original ATP. This Q-phosphate can attack
the seryl adenylate with the formation of Ap4A by the same
in-line displacement mechanism, which leads to PPi release,
but in the reverse direction. A divalent cation is essential for
the reaction and may be directly involved in the stabilisation
of the transition state.
Apart from aaRS ¢re£y luciferase [64] and Ap4A hydrolase
[65] were shown to synthesise Ap4A. Luciferase catalyses the
reactions with formation of activated adenylates (luciferyl) as
intermediates. Ap4A hydrolase can synthesise Ap4A in a sim-
ple back reaction. Apparently, enzymes catalysing the transfer
of nucleoside monophosphate are potential candidates for
producing ApnA [66].
The ability of aaRS to produce Ap4A in vivo demonstrated
by the experiments with overproduction of various aaRS in
E. coli [67] resulted in a 3- to 14-fold increase of intracellular
Ap4A concentration. In control, overproduction of the inac-
tive mutant aaRS did not a¡ect Ap4A level. In vivo overex-
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Table 4
Properties of some eukaryotic ApnA hydrolases
Origin Ap4A Ap3A F3 IS50(Ki) Divalent cations MR Protein Reference
(WM) family
Km
(WM)
kcat
(s31)
Km
(WM)
kcat
(s31)
Activation Inhibition
Human (Fhit) 31.3 0.1 65.0 2.3 ^ Mg2, Mn2, Ca2 Zn2 20642 (K2) HIT [78]
S. pombe nd nd 0.16a ^ Mg2, Mn2, Ca2 Zn2 20672 (K2) HIT [81]
Torpedob 0.48 1 0.54 1.1 1400 Mg2, Mn2, Ca2 nd nd nd [82]
Lupin nd nd nd nd 3 Mg2, Mn2 Ca2 22982 (K) MutT [74]
Human nd nd ^ ^ 40 nd nd 16829 (K) MutT [83]
Porcine 0.8 nd ^ ^ 24 nd nd 16837 (K) MutT [73]
Fire£y 1.9 nd ^ ^ 50 nd nd 16000 (K) nd [68]
nd, not determined; ^, non-measurable; kcat are given to compare the rates of Ap4A and Ap4A hydrolysis. Rate of Ap4A hydrolysis is 1.
aEstimate, catalytic parameters were not measured.
bEnzyme activity was characterised using the preparation of the presynaptic membranes. Activity was tested using etheno derivatives of ApnA.
The supposed subunit composition of the enzymes is given in brackets.
Fig. 2. A hypothesis connecting interferon signalling pathway and
tumour suppression through Ap3A and Fhit hydrolase. FhitWAp3A
is a protein ligand complex. Ovals indicate proteins.
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pression of mammalian TrpRS correlates with the elevated
levels of Ap3A, not Ap4A [38]. Possible participation of the
luciferase in the synthesis of Ap4A in vivo is indirectly sup-
ported by the unusually high level of Ap4A hydrolase activity
in ¢re£y lanterns [68].
Although ApnA can be non-speci¢cally degraded by a vari-
ety of phosphodiesterases and nucleotidases, the major role in
their degradation belongs to the speci¢c enzymes. In E. coli,
Ap4A degradation occurs mainly through symmetrical hydrol-
ysis into two ADP molecules (see [13]). All ApnA are the
substrates for this enzyme, if ns 3. At least one of the reac-
tion products should be NDP. No speci¢c Ap4A hydrolytic
activity was detected in S. cerevisiae. Instead, two isoenzymes
catalysing Ap4A phosphorolysis have been uncovered (see
[12,13]). Recently, the same activity was found in cyanobac-
teria in addition to the symmetrical hydrolase activity [69,70].
Reaction catalysed by Ap4A phosphorylase is described as
Ap4A+PiIATP+ADP.
Most of the higher eukaryotes metabolise Ap4A molecules
by asymmetrical hydrolysis, resulting in formation of ATP
and AMP (reviewed in [13]). Among the lower eukaryotes
the same activity was found in ¢ssion yeast S. pombe [77].
Ap4A hydrolases are speci¢c for tetraphosphates, although
they can also cleave dinucleotides with ¢ve and six phos-
phates. ATP should be one of the reaction products and
Ap3A is poor substrate. There is a speci¢c Ap3A hydrolysing
activity, found in many higher eukaryotes.
Properties of some ApnA hydrolases are listed in Table 4.
According to their primary structures these enzymes are di-
vided into two groups. Human Ap3A hydrolase Fhit (fragile
histidine triad) and S. pombe Ap4A hydrolase belong to the
HIT family and possess 52% sequence identity [56,71].
Although these two enzymes di¡er in their speci¢city toward
Ap4A and Ap3A both activities are inhibited by Zn2 but not
by F3 ions which are inhibitory toward other Ap4A hydrol-
ases [72]. Sequences of human and porcine Ap4A hydrolases
are highly conserved (88% identity) [73] and they display sig-
ni¢cant homology to lupin enzyme [74]. Enzymatic properties
of these three enzymes are similar. Although Ap4A hydrolase
from Torpedo presynaptic plasma membranes di¡ers from the
others by the lack of discrimination between Ap3A and Ap4A,
nevertheless it seems to belong to the same group.
Discovery of the FHIT gene and Ap3A hydrolysing activity
of Fhit [56,71] is probably one of the most interesting ¢ndings
providing a clue for the in vivo function of Ap3A. Fhit be-
longs to the large and ubiquitous group of proteins named
HIT family due to a conserved His-X-His-X-His-X-X se-
quence motif (where X is a hydrophobic amino acid residue)
[75,76]. The FHIT gene was identi¢ed in fragile locus p14.2 of
human chromosome 3 [71]. Exhaustive genetic analysis of this
locus showed deletions and other abnormalities in several
cancer cell lines and primary tumours, leading to the proposal
that the FHIT gene belongs to the family of the tumour sup-
pressor genes and that the Fhit protein may play an essential
role in the oncogenesis [77].
The crystal structures of Fhit and its complexes with sub-
strate analogs were resolved by multiwavelength anomalous
di¡raction [78,79]. This data suggest a metal-independent
mechanism of catalysis involving the formation of a covalent
nucleotidyl phosphohistidyl intermediate. Proposed mecha-
nism and the assignment of the functional roles of the con-
served His residues ¢t well with the results of site-directed
mutagenesis of the Fhit protein [56]. The three-dimensional
structure of Fhit is close to that of protein kinase C interact-
ing protein (PKCI), also a member of HIT family, possessing
two purine-nucleotide binding sites per dimer. However,
PKCI is unable to hydrolyse Ap3A but it slowly hydrolyses
ADP [76,79,80].
5. Perspectives
In spite of obvious heterogeneity of the data on ApnA
functions some interesting consequences follow from the re-
cent developments in this ¢eld. In most studies on ApnA the
attention was drawn to the absolute concentrations of various
ApnA derivatives and often to only one of them, e.g. solely to
Ap4A. Now it has become evident that the whole set of ApnA
from 2 to 6 phosphates possesses biological activity and there-
fore the analysis should be limited to one or two derivatives.
The number of phosphate residues in ApnA bound to AP-
NAB may modulate signal transduction. For instance, if AP-
NAB alternatively binds Ap4A or Ap3A it resembles the bind-
ing of GTP and GDP (also one phosphate group di¡erence)
to G proteins, known to be signal transducers. In G proteins
the GTP/GDP ratio is regulated by GTPase activity of the G
proteins while in APNAB it might be regulated non-enzymati-
cally by di¡erent a⁄nity constants towards ApnA and
Apn31A for the same APNAB. If so, a selective synthesis
or/and degradation of a certain type of ApnA may cause
the shift in proportion of various ApnA derivatives, which
may be utilised by the cell as a signal. TrpRS speci¢cally
produces Ap3A [61] while Fhit degrades it and therefore the
Ap4A/Ap3A ratio can be modulated by changing the activity
of TrpRS/Fhit pair. Possibly, other aaRS can form analogous
pairs with Ap4A hydrolases regulating the Ap4A level as well.
Therefore, the Ap4A/Ap3A ratio may be controlled by many
proteins. The idea that Ap3A/Ap4A ratio is essential for func-
tional activity of these ApnA was already put forward [84].
The protective e¡ect of Fhit towards tumourigenicity [77]
implies that Ap3A and/or Fhit is directly implicated in control
of cell growth and proliferation. No mechanism was suggested
so far to explain the antitumourigenic role of Fhit. Since
apoptosis in human cultured cells is associated with a decrease
in Ap3A level [40], Fhit by binding or hydrolysing Ap3A may
induce apoptosis of transformed cells. As mentioned above
Fhit is a close structural analog of PKCI, a well-known reg-
ulator of cellular signalling pathways, therefore, it may appear
that binding of Ap3A to PKCI can modulate the PKCI ac-
tivity as well. Furthermore, Ap3A serves as preferred substrate
(primer) [85] for the interferon-inducible enzyme 2-5A synthe-
tase and the adenylated derivatives, Ap3A(pA)n may retain
their substrate properties toward Fhit and after hydrolysis
generate ppA(pA)n (n = 1^6) which in turn may activate the
third interferon-inducible enzyme, the RNase L [85]. Appar-
ently, Fhit via Ap3A is tightly interrelated with a cytokine
signalling pathway known to possess strong antiproliferative
activity. The recent important observation [77] that Fhit re-
mained active as a tumour suppressor even when His96Asn
mutant lacking hydrolytic activity was introduced into cancer
cells ¢ts nicely to our model where FhitWAp3A complex is
assumed to be a signal (Fig. 2) rather than Fhit or Ap3A
on their own. The hypothesis that tumour suppressor activity
is associated with Fhit involvement in interferon and/or apop-
totic and/or PKCI regulatory circuits via FhitWAp3A complex
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is experimentally testable. If proven, it will lead to signi¢cant
advancement in our understanding of ApnA functions in gen-
eral and tumour suppression in particular.
In conclusion, it seems possible to consider the whole ApnA
family as a new class of signalling molecules used by eukary-
otic cells to regulate many house-keeping and specialised func-
tions. This class of molecules de¢nitely deserves further and
more detailed biochemical analysis.
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